Auckland, New Zealand 13 August 2025 - CompoundLabs, a leading New Zealand compounding pharmacy, is pleased to announce its official partnership with Bova Group, a global leader in veterinary pharmaceutical compounding. This alliance brings CompoundLabs into a trusted international network of veterinary compounding partners, enabling access to innovative, clinically validated formulations for veterinarians across New Zealand.

As Bova's exclusive New Zealand partner, CompoundLabs joins a global compounding network that includes:

• Stokes Pharmacy (503A) and Epicur Veterinary Compounding (503B) - United States
• Trutina Pharmacy - Canada
• FrancePrep - France
• Bova UK - United Kingdom
• Bova AUS - Australia

This collaboration allows CompoundLabs to bring Bova's evidence-based formulations, many of which have been developed in conjunction with veterinary specialists and clinical research teams, directly to New Zealand's veterinary professionals.

"Veterinarians in New Zealand have long faced challenges accessing specialised treatments that are available overseas," said Graeme Hogan, Business Manager of CompoundLabs. "Partnering with Bova gives us the ability to deliver those treatments, with full confidence in quality, consistency, and scientific backing - right here at home."

Bova Group is widely recognised for its pioneering work in veterinary compounding. Its global partnerships have expanded access to novel treatment options for veterinarians, especially where registered veterinary medicines are unavailable or inadequate. In the Unite States, Stokes Pharmacy and Epicur Veterinary Compounding, sister companies operating under 503A and 503B compounding frameworks, respectively, provide patient-specific and office-use medications to clinics across the country. Similarly, FrancePrep, Trutina and Bova's operations in the UK and Australia serve as critical compounding partners in their respective regions.

"We've built this global network to ensure that no matter where veterinarians are practising, they can access the safest, most effective compounded medications." said Nick Bova, CEO of Bova Group. "CompoundLabs is the perfect partner for New Zealand - experienced, professional, and dedicated to raising the bar in veterinary compounding."

This partnership also reflects the commitment of both Bova and CompoundLabs to compliance and ethical veterinary practice, aligning with the New Zealand Veterinary Association's (NZVA) guidance on the responsible use of compounded medications. Under New Zealand regulations, compounded veterinary medicines may be prescribed when no suitable registered product exists for a specific patient, an essential tool for veterinarians managing complex or rare cases.

"This alliance means New Zealand vets will soon have access to a broader range of compounded treatments, from trusted, evidence-based global formulations to new solutions developed with local clinical needs in mind," Atul Mehta, Managing Director, added. "We're proud to stand alongside some of the most respected veterinary compounded organisations in the world."

About CompoundLabs

CompoundLabs is a long-established New Zealand-owned compounding pharmacy specialising in the preparation of high-quality, custom medications for animal and human patients. With a strong focus on regulatory compliance, scientific integrity, and client service, CompoundLabs supports veterinarians across Aotearoa with flexible treatment solutions. www.compoundlabs.co.nz

About Bova Group

Bova Group is a leading global veterinary compounding company, operating in the UK and Australia and collaborating with strategic partners worldwide. Through research-led innovation and strict quality standards, Bova delivers novel and practical treatment options to support better health outcomes for animals globally. www.bova.vet

Media Contact:

Graeme Hogan, Business Manager

Email: graemeh@compoundlabs.co.nz

Phone: 09 442 1725